• Vaccine Name: SARS-CoV Ad S/N vaccine
• Target Pathogen: SARS-CoV
• Target Disease: Severe Acute Respiratory Syndrome (SARS)
• Type: Recombinant vector vaccine
• Status: Research
• Host Species for Licensed Use: None
• Host Species as Laboratory Animal Model: mouse
• Antigen: S protein, N (See et al., 2006)
• S protein gene of SARS-CoV gene engineering:
  • Type: Recombinant vector construction
  • Description:
  • Detailed Gene Information: Click Here.
• nucleocapsid protein (N) gene of SARS-CoV gene engineering:
  • Type: Recombinant vector construction
  • Description:
  • Detailed Gene Information: Click Here.
• Immunization Route: intranasal immunization
• Description: A combination of two adenovirus-based vectors, one expressing the nucleocapsid (N) and the other expressing the spike (S) protein (See et al., 2006)

Mouse Response

• Host Strain: 129S6/SvEv (See et al., 2006)
• Host age: 6 weeks (See et al., 2006)
• Host gender: Female (See et al., 2006)
• Vaccination Protocol: Mouse was immunized on day 0 and week 4 (See et al., 2006)
• Immune Response: Quantifiable humoral response with presence of SARS-CoV-specific IgG1 and a significant reduction in level of SARS-CoV RNA in lung titers. Production of IFN-γ. (See et al., 2006)
• Challenge Protocol: Mouse was immunized on day 0 and week 4 and then challenged with SARS-COV Tor2 at week 7 (See et al., 2006).
• Efficacy: Partially protected (See et al., 2006)